杨森中国又有4个创新药被纳入国家医保目录,6个产品成功续约

2021-12-03 杨森中国 杨森中国

目前,杨森中国的63个药品品规中,已有58个被纳入国家医保目录,覆盖了肿瘤学、免疫学、神经学、肺动脉高压,以及传染病等中国医疗需求最迫切的治疗领域。

2021年12月3日,国家医疗保障局公布了《国家基本医疗保险、工伤保险和生育保险药品目录(2021年版)》(以下简称:国家医保目录),其中杨森中国旗下4个创新药物首次被纳入国家医保目录,包括兆珂®(达雷妥尤单抗注射液)、安森珂®(阿帕他胺片)和喜达诺®(乌司奴单抗注射液)、喜达诺®(乌司奴单抗注射液静脉输注),将显著为肿瘤和免疫疾病患者提升创新药品的可负担性。不仅如此,杨森还有6款创新药品成功续约,覆盖免疫、传染病、肺动脉高压等重大疾病领域。

杨森中国总裁郑磊表示:“杨森的创新药物被纳入国家医保目录,令我们十分欣喜和振奋。一直以来,与政府共同努力提升创新药的可及性始终是杨森中国的工作重点,我们也紧密配合医保等惠民政策助力实现社会公平和共同富裕,不断兑现对中国患者的长期承诺。作为一家领先的医药创新企业,我们将会持续携手各方合作伙伴,不断解决中国亟待满足的医疗需求,让更多的患者可以用上创新治疗方案,为健康中国的建设做出我们的贡献。”

三个新列名国家医保目录的创新药物及其适应症如下:


兆珂®(达雷妥尤单抗注射液)
与来那度胺和地塞米松联合用药或与硼替佐米和地塞米松联合用药治疗既往至少接受过一线治疗的多发性骨髓瘤成年患者;
单药治疗复发和难治性多发性骨髓瘤成年患者,患者既往接受过包括蛋白酶体抑制剂和免疫调节剂的治疗且最后一次治疗时出现疾病进展;

安森珂®(阿帕他胺片)
用于治疗转移性内分泌治疗敏感性前列腺癌(mHSPC)成年患者;
用于治疗有高危转移风险的非转移性去势抵抗性前列腺癌(NM-CRPC)成年患者;

喜达诺®(乌司奴单抗注射液)
用于对环孢素/甲氨蝶呤(MTX)或PUVA(补骨脂素和紫外线A)等其他系统性治疗不应答、有禁忌或无法耐受的成年中重度斑块状银屑病患者;
用于对传统治疗或肿瘤坏死因子α(TNF-α)拮抗剂应答不足、失应答或无法耐受的成年中重度活动性克罗恩病患者;

喜达诺®(乌司奴单抗注射液静脉输注)
用于对传统治疗或肿瘤坏死因子α(TNF-α)拮抗剂应答不足、失应答或无法耐受的成年中重度活动性克罗恩病患者;

六个成功续约国家医保目录的创新药物及其适应症如下:

类克®(注射用英夫利西单抗)
与甲氨蝶呤合用治疗中重度活动性类风湿关节炎患者;
可用于对于接受传统治疗效果不佳的中重度活动性克罗恩病的成人和 6 岁及以上的儿童患者;
用于治疗瘘管性克罗恩病患者;
用于治疗活动性强直性脊柱炎患者;
用于需系统治疗且对环孢霉素、甲氨蝶呤或光化学疗法等其它系统治疗无效、禁忌或不耐受的慢性重度斑块型银屑病成年患者;
用于接受传统治疗效果不佳、不耐受或有医学禁忌的中重度活动性溃疡性结肠炎成年患者;

斯耐瑞®(富马酸贝达喹啉片)
作为联合治疗的一部分,适用于治疗成人(≥18 岁)耐多药肺结核(MDR-TB)。只有当不能提供其他有效的治疗方案时,方可使用本品;

优拓比®(司来帕格片)
用于治疗肺动脉高压(PAH,WHO 第 1 组)以延缓疾病进展及降低因PAH 而住院的风险;

傲朴舒®(马昔腾坦片)
用于治疗肺动脉高压(PAH,WHO第 1 组),以延缓疾病进展,本品也降低了PAH患者住院治疗;

全可利®(波生坦片,波生坦分散片)
用于治疗 WHO 功能分级 II 级-IV 级的肺动脉高压(PAH)(WHO 第 1 组)的患者,以改善患者的运动能力和减少临床恶化;
波生坦分散片用于年龄≥3 岁的儿科特发性或先天性 PAH 患者中改善肺血管阻力; 

泽维可®(麦格司他胶囊)
用于成人及儿童 C 型尼曼匹克病患者的进行性神经症状的治疗。

目前,杨森中国的63个药品品规中,已有58个被纳入国家医保目录,覆盖了肿瘤学、免疫学、神经学、肺动脉高压,以及传染病等中国医疗需求最迫切的治疗领域。在配合医保目录政策之外,杨森也在积极响应包括惠民保、大湾区药械通政策等多层次医疗保障体系,助力构筑多样化的支付和准入模式,从而改善中国患者的可支付性,为造福中国患者而不懈努力。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1221967, encodeId=ac8a122196e6e, content=<a href='/topic/show?id=e85c33804e5' target=_blank style='color:#2F92EE;'>#医保#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33804, encryptionId=e85c33804e5, topicName=医保)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=清风徐来2022, createdTime=Tue May 24 11:06:36 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006209, encodeId=ef192006209fa, content=<a href='/topic/show?id=74554084960' target=_blank style='color:#2F92EE;'>#国家医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40849, encryptionId=74554084960, topicName=国家医保目录)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Wed Dec 15 10:08:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076812, encodeId=3e9910e68122a, content=Nice , beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5f5648723, createdName=ms7000000482340083, createdTime=Sat Dec 04 12:08:25 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286055, encodeId=571f12860552e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468482, encodeId=e0961468482bb, content=<a href='/topic/show?id=272833882d8' target=_blank style='color:#2F92EE;'>#医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33882, encryptionId=272833882d8, topicName=医保目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3aa6907492, createdName=juliusluan80, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543231, encodeId=40731543231df, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1221967, encodeId=ac8a122196e6e, content=<a href='/topic/show?id=e85c33804e5' target=_blank style='color:#2F92EE;'>#医保#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33804, encryptionId=e85c33804e5, topicName=医保)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=清风徐来2022, createdTime=Tue May 24 11:06:36 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006209, encodeId=ef192006209fa, content=<a href='/topic/show?id=74554084960' target=_blank style='color:#2F92EE;'>#国家医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40849, encryptionId=74554084960, topicName=国家医保目录)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Wed Dec 15 10:08:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076812, encodeId=3e9910e68122a, content=Nice , beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5f5648723, createdName=ms7000000482340083, createdTime=Sat Dec 04 12:08:25 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286055, encodeId=571f12860552e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468482, encodeId=e0961468482bb, content=<a href='/topic/show?id=272833882d8' target=_blank style='color:#2F92EE;'>#医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33882, encryptionId=272833882d8, topicName=医保目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3aa6907492, createdName=juliusluan80, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543231, encodeId=40731543231df, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1221967, encodeId=ac8a122196e6e, content=<a href='/topic/show?id=e85c33804e5' target=_blank style='color:#2F92EE;'>#医保#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33804, encryptionId=e85c33804e5, topicName=医保)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=清风徐来2022, createdTime=Tue May 24 11:06:36 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006209, encodeId=ef192006209fa, content=<a href='/topic/show?id=74554084960' target=_blank style='color:#2F92EE;'>#国家医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40849, encryptionId=74554084960, topicName=国家医保目录)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Wed Dec 15 10:08:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076812, encodeId=3e9910e68122a, content=Nice , beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5f5648723, createdName=ms7000000482340083, createdTime=Sat Dec 04 12:08:25 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286055, encodeId=571f12860552e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468482, encodeId=e0961468482bb, content=<a href='/topic/show?id=272833882d8' target=_blank style='color:#2F92EE;'>#医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33882, encryptionId=272833882d8, topicName=医保目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3aa6907492, createdName=juliusluan80, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543231, encodeId=40731543231df, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
    2021-12-04 ms7000000482340083

    Nice

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1221967, encodeId=ac8a122196e6e, content=<a href='/topic/show?id=e85c33804e5' target=_blank style='color:#2F92EE;'>#医保#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33804, encryptionId=e85c33804e5, topicName=医保)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=清风徐来2022, createdTime=Tue May 24 11:06:36 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006209, encodeId=ef192006209fa, content=<a href='/topic/show?id=74554084960' target=_blank style='color:#2F92EE;'>#国家医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40849, encryptionId=74554084960, topicName=国家医保目录)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Wed Dec 15 10:08:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076812, encodeId=3e9910e68122a, content=Nice , beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5f5648723, createdName=ms7000000482340083, createdTime=Sat Dec 04 12:08:25 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286055, encodeId=571f12860552e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468482, encodeId=e0961468482bb, content=<a href='/topic/show?id=272833882d8' target=_blank style='color:#2F92EE;'>#医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33882, encryptionId=272833882d8, topicName=医保目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3aa6907492, createdName=juliusluan80, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543231, encodeId=40731543231df, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1221967, encodeId=ac8a122196e6e, content=<a href='/topic/show?id=e85c33804e5' target=_blank style='color:#2F92EE;'>#医保#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33804, encryptionId=e85c33804e5, topicName=医保)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=清风徐来2022, createdTime=Tue May 24 11:06:36 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006209, encodeId=ef192006209fa, content=<a href='/topic/show?id=74554084960' target=_blank style='color:#2F92EE;'>#国家医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40849, encryptionId=74554084960, topicName=国家医保目录)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Wed Dec 15 10:08:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076812, encodeId=3e9910e68122a, content=Nice , beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5f5648723, createdName=ms7000000482340083, createdTime=Sat Dec 04 12:08:25 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286055, encodeId=571f12860552e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468482, encodeId=e0961468482bb, content=<a href='/topic/show?id=272833882d8' target=_blank style='color:#2F92EE;'>#医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33882, encryptionId=272833882d8, topicName=医保目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3aa6907492, createdName=juliusluan80, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543231, encodeId=40731543231df, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1221967, encodeId=ac8a122196e6e, content=<a href='/topic/show?id=e85c33804e5' target=_blank style='color:#2F92EE;'>#医保#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33804, encryptionId=e85c33804e5, topicName=医保)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=清风徐来2022, createdTime=Tue May 24 11:06:36 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006209, encodeId=ef192006209fa, content=<a href='/topic/show?id=74554084960' target=_blank style='color:#2F92EE;'>#国家医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40849, encryptionId=74554084960, topicName=国家医保目录)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Wed Dec 15 10:08:47 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076812, encodeId=3e9910e68122a, content=Nice , beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de5f5648723, createdName=ms7000000482340083, createdTime=Sat Dec 04 12:08:25 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286055, encodeId=571f12860552e, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468482, encodeId=e0961468482bb, content=<a href='/topic/show?id=272833882d8' target=_blank style='color:#2F92EE;'>#医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33882, encryptionId=272833882d8, topicName=医保目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3aa6907492, createdName=juliusluan80, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543231, encodeId=40731543231df, content=<a href='/topic/show?id=f2be61592eb' target=_blank style='color:#2F92EE;'>#杨森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61592, encryptionId=f2be61592eb, topicName=杨森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=421413558235, createdName=陆成振, createdTime=Sat Sep 18 02:08:47 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
    2021-09-18 陆成振